Department of Integrated Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, China.
Chin J Integr Med. 2009 Dec;15(6):472-6. doi: 10.1007/s11655-009-0472-6. Epub 2010 Jan 18.
This article presents an integrated overview of Guanxin II (II) regarding its quality control, pharmacokinetics, pharmacology, clinical studies, adverse events, dosage and administration, and its pharmacoeconomic assessment. It has been demonstrated that Guanxin II has beneficial effects on coronary heart disease (CHD). The underlying mechanism was proved to be its anti-ischemic, anti-apoptotic, antioxidative, antiplatelet and anti-inflammatory effects, and so on. Tanshinol, hydroxysafflor yellow A and ferulic acid might be responsible for the cardioprotective effect of Guanxin II. In terms of acquisition cost, Guanxin II is cheaper than other drugs currently available for CHD. Guanxin II is safe, cheap, and effective in the management of CHD. However, the mechanism of its cardioprotective effects has not been completely understood because of limitations in the research methodologies of Chinese medicine. Further work should be carried out with single components such as tanshinol, hydroxysafflor yellow A and ferulic acid, using modern biochemical and molecular methods.
本文综合概述了冠心Ⅱ号的质量控制、药代动力学、药理学、临床研究、不良反应、剂量和给药以及药物经济学评价。研究表明，冠心Ⅱ号对冠心病（CHD）有有益作用。其作用机制被证明具有抗缺血、抗凋亡、抗氧化、抗血小板和抗炎等作用。丹参醇、羟基红花黄色素 A 和阿魏酸可能是冠心Ⅱ号发挥心脏保护作用的物质基础。从采购成本来看，冠心Ⅱ号比目前用于治疗 CHD 的其他药物更便宜。冠心Ⅱ号在治疗 CHD 方面安全、廉价、有效。然而，由于中药研究方法的局限性，其心脏保护作用的机制尚未完全阐明。应使用丹参醇、羟基红花黄色素 A 和阿魏酸等单一成分，并采用现代生化和分子方法开展进一步的工作。
